CoChat

Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials

Esposito, K., Cozzolino, D., Bellastella, G., Maiorino, M. I., Chiodini, P., Ceriello, A., Giugliano, D. · 2011 · Diabetes, Obesity and Metabolism
Cited by 95

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aim: We assessed the efficacy of dipeptidyl peptidase‐4 (DPP‐4) inhibitors vildagliptin, sitagliptin, saxagliptin and alogliptin to reach the haemoglobin HbA1c target of <7% in people with type 2 diabetes. Methods: We conducted an electronic search for randomized controlled trials (RCTs) involving DPP‐4 inhibitors through September 2010. RCTs were included if they lasted at least 12 weeks, included 30 patients or more and reported the proportion of patients reaching the HbA1c target of <7%. Results: A total of 43 RCTs reporting 52 comparisons met the selection criteria, which included 19 101 study participants evaluated for the primary endpoint, 10 467 treated with a DPP‐4 inhibitor and 8634 treated with placebo or a comparator drug. DPP‐4 inhibitors showed a statistically significant reduction in HbA1c compared to placebo and approximately 40% of participants achieved the HbA1c goal of <7%: this was associated with weight neutrality and no greater hypoglycaemia. The reduction of the HbA1c level and the rate of HbA1c goal attainment was not different from comparator drugs, with similar hypoglycaemia, and different effect on weight owing to the nature of comparator (metformin, sulfonylurea or glitazones). Baseline HbA1c was the best predictor for achievement of A1C target (overall weighted r 2 value = 0.410, p < 0.001). Conclusions: A greater proportion of type 2 diabetic patients can achieve the HbA1c goal <7% with DPP‐4 inhibitors compared to placebo, with no weight gain, and no hypoglycaemic risk when used alone; DPP‐4 inhibitors were not different from comparator drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01380.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 95

Metadata

Authors
Esposito, K., Cozzolino, D., Bellastella, G., Maiorino, M. I., Chiodini, P., Ceriello, A., & Giugliano, D.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-05-24
Volume
13
Issue
7
Pages
594-603
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2041342486
Cited by
95
References
13
FWCI
11.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01380.x
The paper
Esposito, K., Cozzolino, D., Bellastella, G., Maiorino, M. I., Chiodini, P., Ceriello, A., & Giugliano, D. (2011). Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01380.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.